Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of lymphoma called nodal T-follicular helper (TFH) cell lymphoma, confirmed by a tissue sample test.
- People who are older than 18 years of age.
- People whose blood counts and organ function meet specific levels — including white blood cells, platelets, liver function, and kidney function — as measured by blood tests (confirm with trial site for exact values).
- People who are relatively well and able to carry out daily activities, rated on a standard scale from 0 (fully active) to 2 (up and about more than half the day).
- People whose heart is pumping at 50% efficiency or more, as measured by an ultrasound of the heart.
- People who are expected to live for more than 3 months.
Who may not be able to join:
- People who have previously received chemotherapy, radiation therapy, or any other cancer treatment.
- People whose lymphoma has spread to the brain or spinal cord.
- People who have uncontrolled heart or blood vessel disease, blood clotting disorders, connective tissue diseases, serious infections, or certain other significant health conditions.
- People who are pregnant or currently breastfeeding.
- People who have an HIV infection.
- People who have had another type of cancer in the past, unless they have been fully cleared of it for 5 or more years — though people who have had certain skin cancers (basal cell or squamous cell carcinoma) or early-stage cervical cancer that has been treated may still be considered eligible (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dehui Zou, Dr., Institute of Hematology & Blood Diseases Hospital, China
Phone: 86-022-23909282
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective Response Rate (ORR); Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.